Overview

Webcast ImageWebcast
Q1 2017 Clovis Oncology, Inc. Earnings Conference Call  (Replay)
05/03/17 at 2:30 p.m. MT
Q1 2017 Clovis Oncology, Inc. Earnings Conference Call
Wednesday, May 3, 2017 2:30 p.m. MT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$52.17
Change (%) Stock is Down 2.87 (5.21%)
Intraday High$55.04
Intraday Low$51.73
Volume1,110,688
Data as of 05/26/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle  
05/23/17Clovis Oncology Announces Presentations at 2017 ASCO Annual Meeting
Updates on rucaparib clinical trials in multiple solid tumors and therapy settings at ASCO Annual Meeting; top-line data from ARIEL3 pivotal study anticipated by end of June BOULDER, Colo.--(BUSINESS WIRE)--May 23, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that abstracts highlighting progress in the rucaparib clinical development program will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting... 
Printer Friendly VersionDownload PDF
05/03/17Clovis Oncology Announces First Quarter 2017 Operating Results
Strong Q1 launch quarter for Rubraca® (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3 target progression events achieved in mid-April Top-line ARIEL3 data anticipated by end of June Multiple clinical trials initiated in early 2017, including TRITON2 and TRITON3 in prostate cancer and Roche-sponsored rucaparib-atezolizumab combination study in gynecologic c... 
Printer Friendly VersionDownload PDF
04/27/17Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment
SALT LAKE CITY, Utah & BOULDER, Colo., April 27, 2017 – Myriad Genetics, Inc. (NASDAQ: MYGN) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis' PARP inhibitor, Rubraca.  Financial terms of the deal were not disclosed.Under the agreement, Myriad will submit a supplementary premarket approval (sPMA) application under its existing PMA for BRACAnalysis CDx to include Rubraca.  The... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
DateTitle
06/02/17
through
06/06/17
Clovis Oncology, Inc. at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
LocationChicago, IL
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.